---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-069193"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T15:13:59.290886+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexeo completes IPO raising $111.5M; Q3 net loss $20.1M as programs advance

## Summary
- IPO in November 2023 raised $111.5M gross; pro forma cash $136.4M, funding operations into Q4 2025.
- Completed enrollment of all four cohorts in LEAD Phase 1/2 trial of LX1001 for APOE4-Alzheimer's.
- Received Canadian CTA clearance for LX2006 (FA cardiomyopathy); first non-US site activated.
- Net loss Q3 2023: $20.1M ($12.36 per share) vs $17.1M ($10.38) in Q3 2022; R&D spend $17.2M.
- Sandi See Tai, M.D. joined as SVP Clinical Development and Operations in October 2023.

## SEC filing metadata
- accession: 0000950170-23-069193
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017023069193/0000950170-23-069193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017023069193/lxeo-20231211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-069193
- JSON: https://secwatch.observer/filing/0000950170-23-069193.json
- Plain text: https://secwatch.observer/filing/0000950170-23-069193.txt

## Key facts
- Earnings Releases
  Lexeo Therapeutics, Inc. reported financial results for the three and nine-months ended September 30, 2023.
  - Period: the three and nine-months ended September 30, 2023
  - Result: reported results
  source text: On December 11, 2023, Lexeo Therapeutics, Inc. (the " Registrant ") issued a press release announcing business highlights and its financial results for the three and nine-months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907108/000095017023069193/0000950170-23-069193-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.